Effects of mood stabilizers on DNA damage in an animal model of mania

Journal of Psychiatry and Neuroscience

Volumn 33, Issue 6, 2008, Pages 516-524

  Andreazza, Ana Cristina ^a,b,c   Kauer Sant'Anna, Marcia ^a,b   Frey, Benicio N ^e   Stertz, Laura ^b   Zanotto, Caroline ^a   Ribeiro, Leticia ^a   Giasson, Karine ^c   Valvassori, Samira S ^d   Réus, Gislaine Z ^d   Salvador, Mirian ^c   Quevedi, João ^d   Gonçalves, Carlos A ^a   Kapczinski, Flavio ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c UNIVERSITY OF CAXIAS DO SUL   (Brazil)

^d UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

Bipolar disorder; DNA damage; Dopamine; Lithium; Models, animal; Oxidative stress

Indexed keywords

AMPHETAMINE; BIOLOGICAL MARKER; CATALASE; DNA; LITHIUM SALT; MOOD STABILIZER; SODIUM CHLORIDE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; VALPROIC ACID;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; ENZYME ACTIVITY; GEL ELECTROPHORESIS; HIPPOCAMPUS; LIPID PEROXIDATION; LYMPHOCYTE; MALE; MANIA; MICRONUCLEUS TEST; MUTAGENESIS; NONHUMAN; OXIDATIVE STRESS; RAT;

EID: 56349115455     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Belmaker RH. Bipolar disorder. N Engl J Med 2004;351:476-86.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-504.
3. Angst F, Stassen HH, Clayton PJ, et al. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002; 68:167-81.
4. Rajkowska, G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 200;48:766-77.
5. Carter CJ. Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability. Schizophr Res 2006;86:1-14.
6. Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 2001;18:685-716.
7. Liu Q, Xie F, Rolstron R, et al Prevention and treatment of Alzheimer disease and aging: antioxidants. Mini Rev Med Chem 2007:7:171-80.
8. Palmieri, B, Sblendorio V. Oxidative stress detection: What for? Part I. Eur Rev Med Pharmacol Sci 2006;10:291-317.
9. Andreazza AC, Cassini C, Rosa AR, et al.Serum S100B and anti-oxidant enzymes in bipolar pateints. J Psychiatr Res 2007;41:523-9.
10. Frey BN, Andreazza AC, Kunz M, et al. Increased oxidative stress and DNA damage in bipolar disorderz a twin-case report. Prog. Neuropsychopharmacol Biol Psychiatry 2007;31:283-5.
11. Zecca L, Youdina MB, Riederer P, et al. Iron, brain ageing and neuropsychopharmacol disorders. Nat Rev Neurosci 2004;5:863-73
12. Cocharane CG. Mechanisms of oxidant injury of cells. Mol Aspects Med 1991;12:137-47.
13. de Vasconcelos AP, Bouilleret V, Riban V, et al. Role of nitric oxide in cerebral blood flow changes during kainate seizures in mice: genetic and pharmacological approaches. Neurobiol Dis 2005;18:270-81.
14. Maluf SW, Erdtmann B. Follow-up study of the genetic damage in lymphocytes of pharmacists and nurses handling antineoplastic drugs evaluated by cytokinesis-block micronuclei analysis and single cell gel electrophoresis assay. Mutat Res 2000;471:21-7.
15. Fenech M, Morley AA. Cytokinesis-block micronucleus method in human lymphocytes: effect of in vivo ageing and low dose X-irradiation. Mutat Res 1986;161:193-8.
16. Andreazza AC, Frey BN, Rombaldi F, et al. DNA damage in bipolar disorder. Psychiatry Res 2007;153:27-32.
17. Simon NM, Smoller JW, McNamara IKL, et al. Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry 2006;60:432-5.
18. Calabrese V, Scapagnini G, Giuffrida Stella AM, et al. Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity. Neurochem Res 2001; 26:739-64.
19. Kato T. The role of mitochondrial dysfunction in bipolar disorder. Drug News Perspect 2006;19:597-602.
20. Konradi C, Eaton M, MacDonald ML, et al. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry 2004;61:300-8.
21. Frey BN, Valvassori SS, Reus GZ, et al. Changes in antioxidant defense enzymes after d-amphetamine exposure: implications as an animal model of mania. Neurochem Res 2006,31:699-703.
22. Frey BN, Martins MR, Petronilho FC, et al. Increased oxidative stress after repeated amphetamine exposure: possible relevance as a model of mania. Bipolar Disord 2006;8:275-80.
23. Frey BN, Valvassori SS, Gomes KM, et al. Increased oxidative stress in submitochondrial particles after chronic amphetamine exposure. Brain Res 2006;1097:224-9.
24. Frey BN, Valvassori SS, Reus GZ, et al. Effects of lithium and valproate on amphetamme-mduced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 2006;31:326-32.
25. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. Guide for the care and use of laboratory animals. National Academy Press. Washington: National Academy Press; 1996.
26. Tice RR, Agurell E, Anderson D, et al. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 2000;35:206-21.
27. Collins A, Dusinska M, Franklin M, et al. Comet assay in human biomonitoring studies: reliability, validation, and applications. Environ Mol Mutagen 1997;30:139-46.
28. Fenech M, Holland N, Chang WP, et al. The HUman MicroNucleus Project-An international collaborative study on the use of the micronucleus technique for measuring DNA damage in humans. Mutat Res 1999;428:271-83.
29. Wills ED. Mechanisms of lipid peroxide formation in animal tissues. Biochem J 1966;99:667-76.
30. Bannister JV, Calabrese L. Assays for superoxide dismutase. Methods Biochem Anal 1987;32:279-312.
31. Aebi H. Catalase in vitro. Methods Enzymol 1984;105:121-6.
32. Shao L, Young LT, Wang JF. Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol Psychiatry 2005;58:879-84.
33. Brunello N. Mood stabilizers: protecting the brain. J Affect Disord 2004;79:S15-20.
34. Manji HK, Moore GJ, Chen G. Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. J Clin Psychiatry 2000;61 (Suppl. 9):82-96.
35. Chuang DM, Chen RW, Chalecka-Franaszek E, et al. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord 2002;4:129-36.
36. Fukumoto T, Morinobu S, Okamoto Y, et al. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl) 2001;158:100-6.
37. Hashimoto R, Hough C, Nakazawa T, et al. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 2002;80:589-97.
38. Chen RW, Chuang DM. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem 1999;274:6039-42.
39. Rowe MK, Chuang DM. Lithium neuroprotection: molecular mechanisms and clinical implications. Expert Rev Mol Med 2004;6:1-18.
40. Pan T, Li X, Xie W, et al. Valproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells. FEBS Lett 2005;579:6716-20.
41. Marchion DC, Bicaku E, Daud AI, et al. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 2005;65:3815-22.
42. Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20:6969-78.
43. Phiel CJ, Zhang F, Huang EY, et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001;276:36734-41.
44. Carli M, Morissette M, Hebert C, et al. Effects of a chronic lithium treatment on central dopamine neurotransporters. Biochem Pharmacol 1997;54:391-7.
45. Berman SB, Hastings TG. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem 1999;73: 1127-37.
46. Burrows KB, Gudelsky G, Yamamoto BK. Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4-methylenedioxymethamphetamine administration. Eur J Pharmacol 2000;398:11-8.
47. Sonsalla PK, Nicklas WJ, Heikkila RE. Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science 1989;243:398-400.
48. Wagner GC, Preston K, Ricaurte GA, et al. Neurochemical similarities between d,l-cathinone and d-amphetamine. Drug Alcohol Depend 1982;9:279-84.
49. Armstrong V, Reichel CM, Doti JF, et al. Repeated amphetamine treatment causes a persistent elevation of glial fibrillary acidic protein in the caudate-putamen. Eur J Pharmacol 2004;488:111-5.
50. Jacobs D, Silverstone T. Dextroamphetamine-induced arousal in human subjects as a model for mania. Psychol Med 1986;16:323-9.
51. Zacny JP, Bodker BK, de Wit H. Effects of setting on the subjective and behavioral effects of d-amphetamine in humans. Addict Behav 1992;17:27-33.
52. Anand A, Verhoeff P, Seneca N, et al. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry 2000;157:1108-14.